This article first appeared on GuruFocus .
Release Date: January 31, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Sun Pharmaceuticals Industries Ltd ( BOM:524715 ) reported a 15.1% increase in sales for Q3 FY26 compared to Q3 FY25, driven by underlying business growth and milestone income.
-
The company's gross margin improved to 81% due to a better product mix.
-
EBITDA for the quarter increased by 23.4% year-over-year, with EBITDA margins rising to 31.9%.
-
The India business recorded a 16.2% growth in sales, with Sun Pharma maintaining its number one position in the Indian pharmaceutical market.
-
The company launched 12 new products in India during the quarter, indicating strong product development and market penetration.
Negative Points
-
The US business saw only a marginal increase of 0.6% in sales, with growth in Innovative Medicines offset by lower sales in the generic business due to increased competition.
-
An exceptional charge of INR4,895 million was recorded due to wage court gratuity and additional provisions for GxMDL final settlement.
-
The effective tax rate increased to 24.3% from 14.7% in the previous year, impacting net profit growth.
-
R&D spend on the innovative portfolio has been reducing over the past few quarters, raising concerns about future pipeline development.
-
The generic business in the US experienced a decline due to specific competition for certain products, affecting overall sales performance.
Q & A Highlights
-
Warning! GuruFocus has detected 4 Warning Signs with BOM:543386.
-
Is BOM:524715 fairly valued? Test your thesis with our free DCF calculator.
Q: Can you elaborate on Sun Pharma's M&A strategy and its focus areas? A: Dilip Shanghvi, Chairman: The US remains a key focus, especially for Innovative Medicines. We are interested in global sales of these medicines. In emerging markets, we are considering smaller acquisitions to integrate with our existing business. We aim to grow organically and will consider acquisitions that strengthen our long-term strategic capabilities.
Q: Why has the growth in Innovative Medicines sales been soft compared to previous quarters? A: Kirti Ganorkar, Managing Director: The growth appears lower due to a high base in Q3 FY25, which included one-time sales to a partner. We recommend evaluating the business on an annual basis rather than quarter-to-quarter.
Q: What is the reason for the reduction in R&D spend on the innovative portfolio? A: Dilip Shanghvi, Chairman: The R&D spend is linked to the commencement of clinical trials. As new trials begin, such as for GL34, we expect an increase in R&D expenditure. We will provide guidance on R&D spend for the next year in the upcoming quarter.
Q: How is Sun Pharma addressing the competition in the US generics market? A: Richard Ascroft, CEO, North America: The generics business is slightly down due to specific competition. We anticipate recovery as we achieve manufacturing compliance and launch new products. The Innovative Medicines segment is expected to continue growing.
Q: Can you provide insights into the gross margin performance and its sustainability? A: Jayashree Satagopan, CFO: The improved gross margin is due to a better product mix, including branded and Innovative Medicines. While we do not provide specific margin guidance, our goal is to sustain performance and achieve our potential.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
